OBJECTIVE: The objective of the study was to evaluate the biological validity of ovarian cancer (OVCA) screening and early detection efforts and to characterize signaling pathways associated with human cancer metastasis and patient survival. STUDY DESIGN: Using genome-wide expression profiling and deoxyribonucleic acid sequencing, we compared pelvic and matched extrapelvic implants from 30 patients with advanced-stage OVCA for expression of molecular signaling pathways and p53 gene mutations. Differentially expressed pathways were further evaluated in a series of primary or early-stage vs metastatic or recurrent cancer samples from 389 ovarian, prostate, and oral cancer patients. Metastasis pathways were also evaluated for associations with survival in 9 independent clinicogenomic datasets from 1691 ovarian, breast, colon, brain, and lung cancer and leukemia patients. The inhibitory effects of 1 pathway (transforming growth factor [TGF]-WNT) on in vitro OVCA cell migration were studied. RESULTS: Pelvic and extrapelvic OVCA implants demonstrated similar patterns of signaling pathway expression and identical p53 mutations. However, we identified 3 molecular pathways/cellular processes that were differentially expressed between pelvic and extrapelvic OVCA samples and between primary/early-stage and metastatic/advanced or recurrent ovarian, oral, and prostate cancers. Furthermore, their expression was associated with overall survival from ovarian cancer (P = .006), colon cancer (1 pathway at P = .005), and leukemia (P = .05). Artesunate-induced TGF-WNT pathway inhibition impaired OVCA cell migration. CONCLUSION: Advanced-stage OVCA has a unifocal origin in the pelvis. Molecular pathways associated with extrapelvic OVCA spread are also associated with metastasis from other human cancers and with overall patient survival. Such pathways represent appealing therapeutic targets for patients with metastatic disease.
OBJECTIVE: The objective of the study was to evaluate the biological validity of ovarian cancer (OVCA) screening and early detection efforts and to characterize signaling pathways associated with humancancer metastasis and patient survival. STUDY DESIGN: Using genome-wide expression profiling and deoxyribonucleic acid sequencing, we compared pelvic and matched extrapelvic implants from 30 patients with advanced-stage OVCA for expression of molecular signaling pathways and p53 gene mutations. Differentially expressed pathways were further evaluated in a series of primary or early-stage vs metastatic or recurrent cancer samples from 389 ovarian, prostate, and oral cancerpatients. Metastasis pathways were also evaluated for associations with survival in 9 independent clinicogenomic datasets from 1691 ovarian, breast, colon, brain, and lung cancer and leukemiapatients. The inhibitory effects of 1 pathway (transforming growth factor [TGF]-WNT) on in vitro OVCA cell migration were studied. RESULTS: Pelvic and extrapelvic OVCA implants demonstrated similar patterns of signaling pathway expression and identical p53 mutations. However, we identified 3 molecular pathways/cellular processes that were differentially expressed between pelvic and extrapelvic OVCA samples and between primary/early-stage and metastatic/advanced or recurrent ovarian, oral, and prostate cancers. Furthermore, their expression was associated with overall survival from ovarian cancer (P = .006), colon cancer (1 pathway at P = .005), and leukemia (P = .05). Artesunate-induced TGF-WNT pathway inhibition impaired OVCA cell migration. CONCLUSION: Advanced-stage OVCA has a unifocal origin in the pelvis. Molecular pathways associated with extrapelvic OVCA spread are also associated with metastasis from other humancancers and with overall patient survival. Such pathways represent appealing therapeutic targets for patients with metastatic disease.
Authors: Debra G B Leonard; Lois B Travis; Kathakali Addya; Graca M Dores; Eric J Holowaty; Kjell Bergfeldt; David Malkin; Betsy A Kohler; Charles F Lynch; Tom Wiklund; Marilyn Stovall; Per Hall; Eero Pukkala; Diana J Slater; Carolyn A Felix Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: Alfiya Akhmetshina; Katrin Palumbo; Clara Dees; Christina Bergmann; Paulius Venalis; Pawel Zerr; Angelika Horn; Trayana Kireva; Christian Beyer; Jochen Zwerina; Holm Schneider; Anika Sadowski; Marc-Oliver Riener; Ormond A MacDougald; Oliver Distler; Georg Schett; Jörg H W Distler Journal: Nat Commun Date: 2012-03-13 Impact factor: 14.919
Authors: Benjamin Margolis; Fanny Dao; Michael Licciardi; Selim Misirlioglu; Narciso Olvera; Sitharam Ramaswami; Douglas A Levine Journal: Gynecol Oncol Rep Date: 2021-08-21
Authors: Krizia Rohena-Rivera; María M Sánchez-Vázquez; Diana A Aponte-Colón; Ingrid S Forestier-Román; Mario E Quintero-Aguiló; Magaly Martínez-Ferrer Journal: PLoS One Date: 2017-04-05 Impact factor: 3.240
Authors: Anna Myriam Perrone; Giulia Girolimetti; Martina Procaccini; Lorena Marchio; Alessandra Livi; Giulia Borghese; Anna Maria Porcelli; Pierandrea De Iaco; Giuseppe Gasparre Journal: Int J Mol Sci Date: 2018-07-13 Impact factor: 5.923
Authors: Jesus Gonzalez Bosquet; Eric J Devor; Andreea M Newtson; Brian J Smith; David P Bender; Michael J Goodheart; Megan E McDonald; Terry A Braun; Kristina W Thiel; Kimberly K Leslie Journal: Sci Rep Date: 2021-03-16 Impact factor: 4.379